ReviewPharmacoEconomics - open2024

Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.

Niklaus Meier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.